Venus Medtech Hangzhou Inc - ESG Rating & Company Profile powered by AI
Check the bottom of the webpage for potential risks for Venus Medtech Hangzhou Inc based on sector, geography and marketcap. Full Sustainability analysis of Venus Medtech Hangzhou Inc can be accessed by logging in. This page displays a zero-cost Sustainability report covering Venus Medtech Hangzhou Inc.
Venus Medtech Hangzhou Inc in the Medical Equipment, Supplies & Distribution industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 2.7, social score of 2.3 and governance score of 5.3.
3.4
Low ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1737978896147)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Bioteque Corp | 8.0 | High |
1 | Amplitude Surgical SA | 8.0 | High |
... | ... | ... | |
224 | West Pharmaceutical Services Inc | 3.6 | Medium |
231 | SeaSpine Holdings Corp | 3.5 | Medium |
232 | Venus Medtech Hangzhou Inc | 3.4 | Medium |
232 | Penumbra Inc | 3.4 | Medium |
234 | Abingdon Health PLC | 3.3 | Medium |
... | ... | ... | |
380 | ZoomMed Inc | 0.0 | Low |
380 | iRay Technology Co Ltd | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1737978896147)
Frequently Asked Questions
Does Venus Medtech Hangzhou Inc have an accelerator or VC vehicle to help deliver innovation?
Does Venus Medtech Hangzhou Inc disclose current and historical energy intensity?
Does Venus Medtech Hangzhou Inc report the average age of the workforce?
Does Venus Medtech Hangzhou Inc reference operational or capital allocation in relation to climate change?
Does Venus Medtech Hangzhou Inc disclose its ethnicity pay gap?
Does Venus Medtech Hangzhou Inc disclose cybersecurity risks?
Does Venus Medtech Hangzhou Inc offer flexible work?
Does Venus Medtech Hangzhou Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Venus Medtech Hangzhou Inc disclose the number of employees in R&D functions?
Does Venus Medtech Hangzhou Inc conduct supply chain audits?
Does Venus Medtech Hangzhou Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Venus Medtech Hangzhou Inc conduct 360 degree staff reviews?
Does Venus Medtech Hangzhou Inc disclose the individual responsible for D&I?
Does Venus Medtech Hangzhou Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Venus Medtech Hangzhou Inc disclose current and / or historical scope 2 emissions?
Does Venus Medtech Hangzhou Inc disclose water use targets?
Does Venus Medtech Hangzhou Inc have careers partnerships with academic institutions?
Did Venus Medtech Hangzhou Inc have a product recall in the last two years?
Does Venus Medtech Hangzhou Inc disclose incidents of discrimination?
Does Venus Medtech Hangzhou Inc allow for Work Councils/Collective Agreements to be formed?
Has Venus Medtech Hangzhou Inc issued a profit warning in the past 24 months?
Does Venus Medtech Hangzhou Inc disclose parental leave metrics?
Does Venus Medtech Hangzhou Inc disclose climate scenario or pathway analysis?
Does Venus Medtech Hangzhou Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Venus Medtech Hangzhou Inc disclose the pay ratio of women to men?
Does Venus Medtech Hangzhou Inc support suppliers with sustainability related research and development?
Does Venus Medtech Hangzhou Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Venus Medtech Hangzhou Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Venus Medtech Hangzhou Inc involved in embryonic stem cell research?
Does Venus Medtech Hangzhou Inc disclose GHG and Air Emissions intensity?
Does Venus Medtech Hangzhou Inc disclose its waste policy?
Does Venus Medtech Hangzhou Inc report according to TCFD requirements?
Does Venus Medtech Hangzhou Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Venus Medtech Hangzhou Inc disclose energy use targets?
Does Venus Medtech Hangzhou Inc disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Venus Medtech Hangzhou Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Venus Medtech Hangzhou Inc
These potential risks are based on the size, segment and geographies of the company.
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.